Skip to main content
. 2019 Oct 8;8(6):505–519. doi: 10.1159/000503032

Fig. 4.

Fig. 4

a Landmark analyses for OS by OR assessed by mRECIST in the sorafenib alone group (landmark Kaplan-Meier curve as function of tumor response at 4 months). b Landmark analyses for OS by OR assessed by mRECIST in the sorafenib alone group (landmark Kaplan-Meier curve as function of tumor response at 6 months). c Landmark analyses for OS by OR assessed by mRECIST in the sorafenib alone group (landmark Kaplan-Meier curve as function of tumor response at 8 months). NR, not reached.